Effects of supraphysiological thyroxine administration in healthy controls and patients with depressive disorders
by
Bauer M, Baur H, Berghofer A, Strohle A,
Hellweg R, Muller-Oerlinghausen B, Baumgartner A.
Department of Psychiatry,
Klinikum Benjamin Franklin,
Freie Universitat Berlin,
Berlin, Germany
J Affect Disord 2002 Apr;68(2-3):285-94

ABSTRACT

BACKGROUND: Thyroxine (T(4)) in supraphysiological doses has been found to be an effective supplemental treatment in open studies for refractory mood disorders. Unexpectedly, only minimal side effects have been reported. The goal of the present study was to investigate whether healthy controls and depressed patients differ in their ability to tolerate supraphysiological doses of T(4). METHODS: This was an 8-week open study to investigate side effects and levels of thyroid hormones in 13 healthy controls and to compare results with those of 13 patients with refractory depression (unipolar and bipolar) undergoing the similar procedures and T(4) dosing regimen in a previous augmentation study. RESULTS: The rate of discontinuation due to side effects was significantly higher in the control group than for the patients (38% versus 0%). The severity of the side effects in the controls increased significantly during treatment with T(4). The side effect scores of the patients were higher than those of the controls prior to T(4) treatment, but did not change significantly during the treatment period. Although the serum concentrations of thyroid hormones rose significantly in both groups, concentrations of fT(3) and fT(4) were significantly higher in the controls. CONCLUSIONS: Healthy controls and depressed patients respond significantly differently to supraphysiological T(4). Healthy controls experience higher elevations of thyroid hormones in response to supraphysiological T(4), thus inducing significantly more side effects and discontinuation. LIMITATIONS: Open-label study; groups were studied at different times; in contrast to healthy controls, depressed patients were also taking antidepressants. CLINICAL RELEVANCE: Studies provide safety and tolerability data on treatment with supraphysiological doses of T(4).

T3
T3 v T4
Dysthymia
Anhedonia
Melancholy
T3 + SSRIs
Bipolar disorder
Thyroid hormones
Augmentation strategies
Triiodothyronine (T3): structure
Hypothyroidism and depression
The thyroid axis and depression
Triiodothyronine (T3) and major depression
Thryoid supplementation and accelerated response
Mechanisms of thyroid augmentation of antidepressants

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family